Zacks Investment Research
30 Sept 2026, 12:46 UTC · 1h ago
Verdict
Source says Buy. We score SCL +1.00 across two claims.
Score confirms the headline.
Buy
Rating stated in the headline
+1.00strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish · 0 new · 2 priced in
AC Immune has seen its Zacks Consensus Estimate for current year earnings increase by 28.6% over the last 60 days.
Priced inanalysis of estimates over last 60 days
So whatThis significant upward drift in consensus often precedes an earnings beat or a positive guidance raise in the next quarterly print.
More positive than 79% of claims this week
Stepan has seen its Zacks Consensus Estimate for current year earnings increase by 10.3% over the last 60 days.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Priced inanalysis of estimates over last 60 days
So whatThe 10.3% increase suggests strengthening fundamentals that may support a higher P/E multiple heading into FY2027.
More positive than 67% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
SCL hasn't traded since this ran. Last close $62.19 (Sep 29); the reaction starts at the next open.
SCL chart →